风险算法对肺动脉高压临床试验的富集效益
本研究汇总三项肺动脉高压临床试验基线数据,比较三种风险评分(French评分、COMPERA、REVEAL 2.0)预测临床恶化的能力。所有风险算法的AUC均显著优于按NYHA功能分级预测,其中REVEAL 2.0在AMBITION和GRIPHON中节省样本量和时间最多。在GRIPHON中,纳入REVEAL评分≥8的患者经济效益最大。
要点
- REVEAL 2.0风险分层在AMBITION和GRIPHON中富集效益最佳,但SERAPHIN因缺少NT-proBNP输入而表现不佳。
- 所有风险算法的预测性能(AUC)均显著优于NYHA功能分级。
- GRIPHON成本分析显示,纳入REVEAL评分≥8的患者财务收益最大。
核心结论
- 风险算法用于肺动脉高压试验富集是可行的,但需进一步研究。
研究设计与样本
- 汇总AMBITION、SERAPHIN和GRIPHON三项肺动脉高压临床试验的基线数据并标准化。
- 使用受试者工作特征曲线评估各算法在汇总安慰剂队列中预测临床恶化的性能。
- 通过功效模拟确定多种富集策略的样本量和治疗时间缩减,并对GRIPHON进行成本分析。
主要发现
- 所有风险算法的曲线下面积均显著优于按纽约心脏协会功能分级预测。
- REVEAL 2.0风险分组在AMBITION和GRIPHON中对所有富集策略提供最大的时间和样本量节省。
- REVEAL 2.0因缺乏N末端-proB型利钠肽等输入,在SERAPHIN中表现不佳。
- GRIPHON成本分析表明,纳入REVEAL评分≥8的患者财务收益最大。
关键数值与推荐
- 在GRIPHON中,纳入REVEAL评分≥8的患者财务收益最大。
临床怎么用
- 可考虑使用经验证的风险算法(如REVEAL 2.0)对肺动脉高压临床试验进行预后富集,以降低样本量和时间需求。
- 应用富集策略时需确保风险算法所需输入变量(如NT-proBNP)完整可用。
局限性
- 本研究为初步研究,需进一步调查验证。
- REVEAL 2.0在SERAPHIN中因缺乏适当输入变量而表现受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Event-driven primary endpoints are increasingly used in pulmonary arterial hypertension clinical trials, substantially increasing required sample sizes and trial lengths. The U.S. Food and Drug Administration advocates the use of prognostic enrichment of clinical trials by preselecting a patient population with increased likelihood of experiencing the trial's primary endpoint.Objectives: This study compares validated clinical scales of risk (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, the French score, and Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management [REVEAL] 2.0) to identify patients who are likely to experience a clinical worsening event for trial enrichment.Methods: Baseline data from three pulmonary arterial hypertension clinical trials (AMBITION [a Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension], SERAPHIN [Study of Macitentan on Morbidity and Mortality in Patients with Symptomatic Pulmonary Arterial Hypertension], and GRIPHON [Selexipag in Pulmonary Arterial Hypertension]) were pooled and standardized. Receiver operating curves were used to measure each algorithm's performance in predicting clinical worsening within the pooled placebo cohort. Power simulations were conducted to determine sample size and treatment time reductions for multiple enrichment strategies. A cost analysis was performed to illustrate potential financial savings by applying enrichment to GRIPHON.Measurements and Main Results: All risk algorithms were compared using area under the receiver operating curve and substantially outperformed prediction per New York Heart Association Functional Class. The REVEAL 2.0's risk grouping provided the greatest time and sample size savings in AMBITION and GRIPHON for all enrichment strategies but lacked appropriate inputs (i.e., N-terminal-proB-type natriuretic peptide) to perform as well in SERAPHIN. Cost analysis applied to GRIPHON demonstrated the greatest financial benefit by enrolling patients with a REVEAL score ≥8.Conclusions: This preliminary study demonstrates the feasibility of risk algorithms for pulmonary arterial hypertension trial enrichment and a need for further investigation.
引用
- Scott JV, Garnett CE, Kanwar MK, et al. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials. Am J Respir Crit Care Med. 2021. PMID: 32937078. doi:10.1164/rccm.202002-0357OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。